Form 4: Arcus Biosciences GC Exercises Stock Options

General Counsel Carolyn C. Tang exercised 34,090 stock options in Arcus Biosciences, Inc. on June 11, 2026.

Summary

• Carolyn C. Tang, General Counsel of Arcus Biosciences, Inc., exercised 34,090 stock options.
• The exercise price for these options was $2.574 per share.
• Following the transaction, the reporting person holds 184,607 shares of common stock.
• The transaction included the full exercise of the remaining vested option grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard administrative exercise of vested equity by an executive.

Positives

• The reporting person maintains a significant equity stake of 184,607 shares in the company.
• The exercise of options demonstrates alignment between executive interests and long-term shareholder value.

Negatives

• None identified in this filing.

Risks

• Standard market risks associated with equity ownership in a biotechnology company.

Future Outlook

Not applicable as this is a routine disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that routine option exercises by legal executives are standard corporate governance events and generally do not signal a change in company strategy or outlook.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive compensation and equity management.
• The exercise price is consistent with historical grant structures typical for biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine insider transaction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Stock Options, Biotechnology